Comparison of Intravitreal Bevacizumab and Triamcinolone Acetonide With Intravitreal Bevacizumab Alone in Macular Edema Secondary to Central Retinal Vein Occlusion

Hayatabad Medical Complex1 site in 1 country30 target enrollmentJune 10, 2018

ConditionsCentral Retinal Vein Occlusion With Macular Edema

InterventionsGroup A

DrugsGroup A

Overview

Phase: Not Applicable
Intervention: Group A
Conditions: Central Retinal Vein Occlusion With Macular Edema
Sponsor: Hayatabad Medical Complex
Enrollment: 30
Locations: 1
Primary Endpoint: Visual Acuity
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

To compare the effect of intravitreal-Bevacizumab and Triamcinolone with intravitreal-Bevacizumab alone on visual acuity and central foveal thickness in patients with macular edema secondary to central retinal vein occlusion.

Registry

clinicaltrials.gov

Start Date

June 10, 2018

End Date

December 10, 2018

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Hayatabad Medical Complex

Responsible Party

Principal Investigator

Yousaf Jamal Mahsood

Dr.

Hayatabad Medical Complex

Eligibility Criteria

Inclusion Criteria

•Subjects of either gender, age 40-80 years, having macular edema secondary to CRVO, Best-corrected visual acuity (BCVA) of less than or equal to 0.3 on Log MAR chart (Snellen equivalent of 6/12), Central foveal thickness CFT greater than or equal to 250 microns on Heidelberg Spectralis Spectral Domain Optical coherence tomography (SD-OCT) and clinical diagnosis of CRVO.

Exclusion Criteria

•previously received laser treatment and/or intravitreal injection of any Anti-VEGF agent, having one eye, diagnosed case of glaucoma, family history of glaucoma, young patient, and anyone who has received any treatment for CRVO before presenting to us.

Arms & Interventions

Group A

A single injection of triamcinolone acetonide (Kenacort-AⓇ). (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml) was given at the start of the treatment whereas intravitreal bevacizumab (1.25mg/0.05ml) was repeated monthly for 3 months.

Intervention: Group A